Post-licensing safety of fosamprenavir in HIV-infected children in Europe

作者：Judd Ali^*; Trinh Duong; Galli Luisa; Goetghebuer Tessa; Ene Luminita; Noguera Julian Antoni; Ramos Amador Jose Tomas; Pimenta Jeanne Marie; Thorne Claire; Giaquinto Carlo

来源：Pharmacoepidemiology and Drug Safety, 2014, 23(3): 321-325.

DOI：10.1002/pds.3543

• pharmacovigilance
• epidemiology
• fosamprenavir
• safety
• HIV
• children
• pharmacoepidemiology

PurposeFosamprenavir, combined with low-dose ritonavir (FPV/r), is indicated for treatment of HIV-infected children aged 6years in Europe. Our purpose was to assess the safety of licensed use of FPV/r in HIV-infected children reported to six cohorts in the European Pregnancy and Paediatric HIV Cohort Collaboration.
MethodsRetrospective analysis of individual patient data for all children aged 6-18years taking the licensed dose of FPV up to 31/12/10. Adverse events (clinical events and absolute neutrophil counts, total cholesterol and triglycerides, and alanine transaminase) were summarised and DAIDS gradings characterised severity.
ResultsNinety-two HIV-infected children aged 6-18years took the licensed dose, comprising 3% of the total number of children in follow-up in participating cohorts. Median age at antiretroviral therapy initiation was 6years (interquartile range 1-11years), and median age at start of FPV/r was 15years (12-17years). Estimated median time on an FPV-containing regimen was 52months, with a total of 266.9 patient years of exposure overall. Half (54%) were on an FPV-containing regimen at last follow-up. Rates of grade 3/4 events were generally low for all biochemical toxicity markers, and no serious adverse events considered to be causally related to FPV/r were reported.
ConclusionsResults suggest that long-term licensed dose FPV-containing regimens appear to be generally well tolerated with few reported toxicities in HIV-infected children in Europe, although relatively infrequently prescribed. No serious events were reported.

• 出版日期2014-3